Cytori Updates Phase 3 Scleroderma STAR Trial, Enrolls 60th Patient
News, Scleroderma
Cell therapy company Cytori Therapeutics announced that its Phase 3 STAR clinical trial has enrolled and treated its 60th patient, reaching 75 percent of the target enrollment (80 patients). Safety data review ... Read more